Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels

Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels

Realizing the reported misuse of human growth hormone (GH), investigation of a safe alternative mechanism for increasing endogenous GH is needed. Several GH secretagogues are available, including GH-releasing peptides (GHRPs) GHRP-2 and GHRP-6, and the GH-releasing hormone analog, sermorelin (SERM)....

Full description

Bibliographic Details
Main Authors:	John T. Sigalos, Alexander W. Pastuszak, Andrew Allison, Samuel J. Ohlander, Amin Herati, Mark C. Lindgren, Larry I. Lipshultz
Format:	Article
Language:	English
Published:	SAGE Publishing 2017-11-01
Series:	American Journal of Men's Health
Online Access:	https://doi.org/10.1177/1557988317718662

Similar Items

Hypothalamic actions of growth hormone secretagogues
by: Kumarnsit, Ekkasit
Published: (2003)

Neuroprotective actions of ghrelin and growth hormone secretagogues
by: Laura M. Frago, et al.
Published: (2011-09-01)

Transgenic studies of growth hormone secretagogues physiology
by: Balthasar, Nina
Published: (2001)

Growth Hormone Secretagogues and the Regulation of Calcium Signaling in Muscle
by: Elena Bresciani, et al.
Published: (2019-09-01)

The synthesis of a small library of prospective growth hormone secretagogues
by: Pejović Vojislav, et al.
Published: (1999-01-01)

Growth hormone secretagogues: history, mechanism of action, and clinical development
by: Junichi Ishida, et al.
Published: (2020-01-01)

The Growth Hormone Secretagogue Receptor: Its Intracellular Signaling and Regulation
by: Yue Yin, et al.
Published: (2014-03-01)

The synthesis of a small library of prospective growth hormone secretagogues
by: JELENA JOKSIMOVIC, et al.
Published: (1999-10-01)

Long and short term effects of growth hormone secretagogues on body composition
by: Lall, Sabrina
Published: (2001)

Molecular characterization of growth hormone secretagogue receptor in black seabream, acanthopagrus schlegeli.
Published: (2003)

Testosterone versus clomiphene citrate in managing symptoms of hypogonadism in men
by: Pranav Dadhich, et al.
Published: (2017-01-01)

Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus?
by: Elizabeth C Hersch, et al.
Published: (2008-03-01)

LEAP2 deletion in mice enhances ghrelin's actions as an orexigen and growth hormone secretagogue
by: Kripa Shankar, et al.
Published: (2021-11-01)

Ghrelin and the Growth Hormone Secretagogue Receptor Axis : A Genetic Analysis of Regulatory Function In Growth and Metabolism in the Human
by: Gueorguiev, Maria
Published: (2007)

Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer
by: Zachary A.P. Wintrob, et al.
Published: (2017-04-01)

Regional Differences in the Ghrelin-Growth Hormone Secretagogue Receptor Signalling System in Human Heart Disease
by: Rebecca Sullivan, BSc, et al.
Published: (2021-02-01)

Biological activity of a new Growth hormone secretagogue: study in fish and murine cell line
by: Rebeca Martínez
Published: (2016-09-01)

Development and Characterization of an F-labeled Ghrelin Peptidomimetic for Imaging the Cardiac Growth Hormone Secretagogue Receptor
by: Ahmed Abbas MSc, et al.
Published: (2018-11-01)

Insulin Resistance and Hypogonadism
by: Shahana Shermin, et al.
Published: (2013-05-01)

LEAP2 Impairs the Capability of the Growth Hormone Secretagogue Receptor to Regulate the Dopamine 2 Receptor Signaling
by: Emilio R. Mustafá, et al.
Published: (2021-08-01)

The Ghrelin/Growth Hormone Secretagogue Receptor System Is Involved in the Rapid and Sustained Antidepressant-Like Effect of Paeoniflorin
by: Yuan Zhang, et al.
Published: (2021-02-01)

Ghrelin transport across the blood–brain barrier can occur independently of the growth hormone secretagogue receptor
by: Elizabeth M. Rhea, et al.
Published: (2018-12-01)

Preserving fertility in the hypogonadal patient: an update
by: Ranjith Ramasamy, et al.
Published: (2015-04-01)

Editorial Foreword: Comments on "Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging" || FREE PAPER ||
by: Richard F Walker
Published: (2008-03-01)

Growth hormone deficiency and central hypogonadism in retired professional football players
by: Gábor László Kovács, et al.
Published: (2016-12-01)

Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia.
by: Ambavane V, et al.
Published: (2002-07-01)

Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
by: Miao-Miao Zhao, et al.
Published: (2021-09-01)

Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium.
by: Yi Ma, et al.
Published: (2012-01-01)

Purification and characterization of rat des-Gln14-Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor.
by: Hosoda, Hiroshi
Published: (2011)

Adenylosuccinate Is an Insulin Secretagogue Derived from Glucose-Induced Purine Metabolism
by: Jessica R. Gooding, et al.
Published: (2015-10-01)

Integration of Cell-Free Expression and Solid-State NMR to Investigate the Dynamic Properties of Different Sites of the Growth Hormone Secretagogue Receptor
by: Emelyne M. Pacull, et al.
Published: (2020-10-01)

Contribution of growth hormone secretagogue receptor (GHSR) signaling in the ventral tegmental area (VTA) to the regulation of social motivation in male mice
by: Su-Bin Park, et al.
Published: (2021-04-01)

Hypogonadism, ADAM, and hormone replacement
by: Michael R. Pinsky, et al.
Published: (2010-06-01)

Hypogonadism and cardiovascular diseases in men
by: Safail Ogly Gamidov, et al.
Published: (2011-10-01)

Hypogonadism and voiding dysfunction in men
by: William J. Huang
Published: (2016-06-01)

Normogonadotropic hypogonadism in men with obesity
Published: (2009-09-01)

Circulating adipokines data associated with insulin secretagogue use in breast cancer patients
by: Zachary A.P. Wintrob, et al.
Published: (2017-02-01)

A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agen.
by: Kenji Sugawara, et al.
Published: (2016-01-01)

Fasting induces remodeling of the orexigenic projections from the arcuate nucleus to the hypothalamic paraventricular nucleus, in a growth hormone secretagogue receptor–dependent manner
by: Agustina Cabral, et al.
Published: (2020-02-01)

Correction: A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agent.
by: PLOS ONE Staff
Published: (2017-01-01)